帕金森病（PD）是常见的神经退行性疾病，病因及发病机制尚不清楚，临床上以补充脑内多巴胺含量为主的"对症治疗"无法阻止病情的进一步加重。α-突触核蛋白是PD特异性病理标志路易氏小体的主要成分，该蛋白异常能导致多巴胺能神经元的死亡。我国传统的补益中药在治疗PD方面很有优势，但这些补益中药的活性成分目前尚不清楚。本团队拟在对α-突触核蛋白功能研究的基础上，开展以下研究：（1）拟结合现代生物学新技术，从α-突触核蛋白的过表达、突变、异常修饰及截断体等多方面，在分子、细胞、动物三种水平上建立以α-突触核蛋白为靶点的系统模型，为开发具有我国自主知识产权的抗PD新药提供崭新平台；（2）筛选补益中药中具有抗α-突触核蛋白损伤的活性成分，并阐明其神经保护机制，以期发现有较强活性的抗PD药物。

Parkinson's disease(PD) is a common neurodegeneration disease, but its mechanism remains obscure. The symptomatic therapy of Levo-dopa supplementation couldn't inhibit the progress of PD.α-Synuclein is the main protein in the Lewy bodies, which is the specific marker of PD, and its abnormal expression could lead to the death of dopaminergic neurons. The traditional tonic Chinese herbs have superiority on treating "asthenia syndrome" and abundant foundation on PD treatment，but the active ingredients need to be further clarified. The purpose of this project is to: (1) Construct systemic models targeting α-synuclein associated with its overexpression, mutation, modification, truncation and so on, to exploit the anti-PD innovative drug in molecule, cell and animal models; (2) Screen neuroprotective ingredients against α-synuclein toxicity and elucidate their neuroprotective mechanism, explore the lead compound for PD.